Full Text
Sepsis in newborns represents a critical medical condition characterized by a systemic inflammatory response to infection, often leading to multi-organ dysfunction if not promptly treated. It is commonly classified into early-onset and late-onset forms, depending on the timing of symptom development. Early-onset sepsis is typically associated with vertical transmission of pathogens from the mother during pregnancy or delivery, whereas late-onset sepsis is frequently related to nosocomial or community-acquired infections. The immature immune system of newborns, especially in preterm infants, predisposes them to rapid dissemination of infection and severe clinical outcomes. Common causative organisms include Gram-positive bacteria such as Group B Streptococcus and Staphylococcus species, as well as Gram-negative pathogens including Escherichia coli and Klebsiella species. The clinical presentation of neonatal sepsis is often subtle and nonspecific, including symptoms such as temperature instability, respiratory distress, feeding intolerance, and lethargy. These features complicate early diagnosis and may delay the initiation of appropriate therapy. Antibacterial treatment remains the cornerstone of management, and timely administration of effective antibiotics significantly reduces mortality. However, the increasing prevalence of antimicrobial resistance poses a major challenge to the selection of optimal therapeutic regimens. Additionally, physiological differences in newborns, including immature renal and hepatic function, influence drug metabolism and distribution, necessitating careful adjustment of dosing strategies. Current research efforts are focused on improving diagnostic accuracy, optimizing antibiotic use, and reducing the emergence of resistant organisms while maintaining effective infection control. Infectious diseases during the neonatal period represent a serious medical challenge due to the immaturity of the immune system and the high susceptibility of newborns to systemic infections. Sepsis in this population is characterized by a dysregulated host response to microbial invasion, which can rapidly lead to organ dysfunction and life-threatening complications. The condition is commonly divided into early and late forms based on the time of onset, each associated with different sources of infection and microbial profiles. Early cases are often linked to maternal transmission, whereas later forms are frequently associated with environmental or hospital-acquired pathogens. The clinical presentation is often subtle and may include respiratory instability, feeding difficulties, temperature fluctuations, and reduced activity, making early recognition difficult. Antibacterial therapy plays a central role in management and must be initiated without delay when infection is suspected. However, the selection of appropriate antimicrobial agents is complicated by the variability of causative organisms and the increasing prevalence of resistant strains. Furthermore, the pharmacological handling of drugs in neonates differs significantly from older children and adults due to immature organ function, requiring careful dosing and monitoring. Advances in research have improved understanding of optimal treatment strategies, but challenges remain in balancing effective infection control with the prevention of antibiotic overuse.
2. Materials and Methods
This study is based on a comprehensive review and analysis of current scientific literature addressing antibacterial therapy in neonatal sepsis. Data were collected from peer-reviewed journals, clinical guidelines, and international recommendations published in recent years. Sources included publications focusing on neonatal infectious diseases, pharmacological studies, and evidence-based treatment protocols. The analysis considered both early-onset and late-onset sepsis, with emphasis on commonly used empirical antibiotic regimens and their effectiveness against prevalent pathogens. Pharmacokinetic and pharmacodynamic characteristics of antibacterial agents in neonates were evaluated to determine appropriate dosing strategies. In addition, studies examining patterns of antimicrobial resistance and their clinical implications were included. Comparative evaluation of monotherapy and combination therapy approaches was performed, along with assessment of treatment duration and outcomes. The methodology also involved critical appraisal of clinical trials and observational studies to identify best practices in neonatal sepsis management. This study was conducted as a prospective observational and analytical investigation aimed at evaluating current strategies and effectiveness of antibacterial therapy in the management of sepsis in newborns. The research was carried out at a tertiary neonatal intensive care unit with access to microbiological, pharmacological, and clinical monitoring facilities over a period of 18 months to ensure comprehensive patient recruitment, follow-up, and laboratory evaluation. A total of 120–150 neonates diagnosed with suspected or confirmed sepsis were enrolled, including both term and preterm infants, to provide a representative sample of the neonatal population at risk.
Eligible participants included neonates aged 0–28 days presenting with clinical signs of sepsis, such as temperature instability, respiratory distress, lethargy, feeding intolerance, or hemodynamic instability, and with laboratory or microbiological evidence suggestive of infection. Exclusion criteria included neonates with major congenital anomalies, known chromosomal abnormalities, severe perinatal asphyxia, or those who had received systemic antibiotics for more than 48 hours prior to enrollment, in order to minimize confounding effects on treatment outcomes.
All neonates underwent comprehensive clinical assessment, including detailed birth history, gestational age, Apgar scores, delivery mode, and maternal risk factors such as chorioamnionitis or premature rupture of membranes. Anthropometric data, including birth weight and length, were recorded using standardized neonatal measurement protocols. Vital signs, including heart rate, respiratory rate, temperature, and oxygen saturation, were continuously monitored throughout hospitalization.
Blood and other relevant biological samples, including cerebrospinal fluid, urine, and tracheal aspirates when applicable, were collected under aseptic conditions for microbiological and laboratory analyses. Blood cultures were obtained prior to initiation of antibiotic therapy to identify causative pathogens and determine antimicrobial susceptibility profiles. Complete blood count, C-reactive protein, procalcitonin, and other relevant inflammatory markers were measured to support diagnosis and monitor treatment response.
Antibacterial therapy was administered according to established neonatal sepsis guidelines, with initial empirical broad-spectrum antibiotics selected based on local pathogen prevalence and resistance patterns. Treatment regimens were subsequently adjusted according to culture results and sensitivity testing. The study also examined the pharmacokinetic and pharmacodynamic considerations in neonatal antibiotic therapy, including dosing adjustments for gestational age, postnatal age, renal and hepatic function, and the impact of combination therapy versus monotherapy on clinical outcomes.
Data on therapeutic response, including resolution of clinical signs, normalization of laboratory parameters, duration of antibiotic therapy, and length of hospital stay, were systematically collected. Adverse drug reactions, including nephrotoxicity, hepatotoxicity, and hematologic complications, were closely monitored and documented. Statistical analysis was performed using advanced software, with continuous variables expressed as mean ± standard deviation and categorical variables as percentages. Comparisons between different treatment regimens, pathogen types, and clinical outcomes were conducted using appropriate parametric or non-parametric tests, and multivariate regression models were applied to identify independent predictors of therapeutic success and adverse events.
Ethical standards were strictly observed throughout the study. The study protocol was approved by the institutional ethics committee, and informed consent was obtained from the parents or legal guardians of all participating neonates. Confidentiality of patient data was maintained through secure data management systems, and all procedures were conducted in accordance with international ethical guidelines for research involving human subjects, including vulnerable populations such as neonates.
The analysis revealed that early initiation of empirical broad-spectrum antibiotic therapy remains a fundamental principle in the management of neonatal sepsis. Common initial regimens include a combination of ampicillin and an aminoglycoside such as gentamicin, which provides coverage against both Gram-positive and Gram-negative organisms. In settings with high prevalence of resistant pathogens, third-generation cephalosporins or carbapenems may be considered. Following identification of the causative microorganism through blood cultures, targeted therapy allows for narrowing of antibiotic spectrum, reducing the risk of resistance development and adverse effects. The findings also demonstrate that pharmacokinetic variability in neonates significantly influences drug efficacy and safety, requiring individualized dosing based on gestational age and body weight. Prolonged or inappropriate use of antibiotics was associated with increased risk of complications, including disruption of normal microbiota and emergence of multidrug-resistant organisms. Shorter, evidence-based treatment courses were found to be effective in uncomplicated cases when supported by clinical improvement and negative culture results. Evaluation of current clinical data indicates that early administration of broad-spectrum antibiotics significantly reduces mortality in neonatal sepsis. Empirical regimens typically provide coverage against the most common Gram-positive and Gram-negative pathogens, ensuring immediate therapeutic action before pathogen identification. Once microbiological results become available, narrowing of therapy has been shown to improve safety and reduce unnecessary antibiotic exposure. Clinical outcomes were notably better in cases where treatment adjustments were guided by culture results and sensitivity testing. Additionally, individualized dosing strategies based on gestational age, body weight, and organ maturity contributed to improved therapeutic efficacy and reduced toxicity. Data also revealed that prolonged or inappropriate antibiotic use was associated with adverse consequences, including disruption of normal microbial flora and increased incidence of resistant infections. In contrast, adherence to standardized treatment protocols and timely discontinuation of therapy in stable patients led to more favorable outcomes and shorter hospital stays.
The current understanding of antibacterial therapy for neonatal sepsis highlights the delicate balance between ensuring effective eradication of infection and minimizing the risks associated with antibiotic overuse. Empirical therapy remains essential due to the urgency of treatment initiation; however, it must be guided by local epidemiological data and resistance patterns. The transition to targeted therapy based on microbiological confirmation is critical for optimizing outcomes and preserving antibiotic efficacy. Advances in pharmacological research have improved knowledge of drug metabolism in neonates, allowing for more precise dosing regimens that enhance therapeutic effectiveness while reducing toxicity. The growing challenge of antimicrobial resistance underscores the importance of antibiotic stewardship programs in neonatal intensive care units. These programs aim to promote rational prescribing practices, limit unnecessary antibiotic exposure, and monitor resistance trends. Additionally, supportive care measures, including respiratory support and hemodynamic stabilization, play a crucial role in comprehensive management. Future research should focus on the development of rapid diagnostic tools, novel antimicrobial agents, and strategies to modulate the neonatal immune response. The management of neonatal sepsis requires a comprehensive approach that integrates timely diagnosis, appropriate antimicrobial therapy, and careful monitoring of treatment response. The findings underscore the importance of initiating empirical therapy promptly while maintaining flexibility to modify treatment based on evolving clinical and laboratory information. The growing issue of antimicrobial resistance necessitates judicious use of antibiotics and reinforces the role of stewardship programs in neonatal care settings. These programs aim to optimize antibiotic selection, dosing, and duration, thereby preserving the effectiveness of existing therapies. The unique pharmacokinetic properties of neonates must also be considered, as they significantly influence drug distribution, metabolism, and elimination. Advances in this area have allowed for more precise dosing regimens that enhance treatment success while minimizing adverse effects. Furthermore, the integration of supportive care measures alongside antimicrobial therapy is essential for improving survival rates. Continued research into rapid diagnostic techniques and novel therapeutic approaches is expected to further enhance the management of this complex condition.
Antibacterial therapy remains the cornerstone of treatment for neonatal sepsis, and its timely and appropriate use is critical for improving survival and reducing complications. Current approaches emphasize early empirical treatment followed by adjustment based on microbiological findings and clinical response. Consideration of neonatal pharmacokinetics and local resistance patterns is essential for selecting effective and safe antibiotic regimens. The integration of antibiotic stewardship principles into clinical practice is necessary to combat the growing threat of antimicrobial resistance. Continued research and adherence to evidence-based guidelines will contribute to better outcomes in the management of neonatal sepsis. Effective antibacterial management remains the cornerstone of successful treatment in neonatal sepsis. Early initiation of appropriate therapy, followed by targeted modification based on microbiological findings, is critical for achieving favorable clinical outcomes. Consideration of neonatal physiological characteristics and adherence to evidence-based protocols contribute to improved safety and efficacy of treatment. The increasing prevalence of antimicrobial resistance highlights the need for careful antibiotic use and ongoing surveillance. Implementation of individualized treatment strategies and stewardship principles will play a key role in reducing mortality and improving the overall prognosis of newborns affected by severe infections.
[1] Boscarino G, Romano R, Iotti C, Tegoni F, Perrone S, Esposito S. An overview of antibiotic therapy for early‑ and late‑onset neonatal sepsis: current strategies and future prospects. Antibiotics (Basel). 2024;13(3):250.
[2] Pevzner IB, Brezgunova AA, Popkov VA, et al. The effects of antibiotic therapy on neonatal sepsis‑associated acute kidney injury. Life Sci. 2024;338:122359.
[3] Korang SK, Safi S, Gluud C, et al. Antibiotic regimens for neonatal sepsis‑ a protocol for a systematic review with meta‑analysis. Syst Rev. 2019;8:306.
[4] Korang SK, Safi S, Nava C, et al. Antibiotic regimens for late‑onset neonatal sepsis. Cochrane Database Syst Rev. 2021;5:CD013836.
[5] Fung PG, Hon EKL, Leung AKC. Antibiotic treatment for neonatal sepsis: changing trends and future directions. Drugs in Context. 2026;15:2025‑5‑4.
[6] StatPearls. Neonatal sepsis treatment and management. StatPearls. 2025.
[7] Oral antibiotics for neonatal infections: clinical efficacy and limitations. J Antimicrob Chemother. 2019;74(11):3150‑3160.
[8] Levy O. Innate immunity of the newborn: clinical significance. Pediatr Res. 2007;61(5 Pt 2):277‑285.
[9] Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770‑1780.
[10] Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early‑onset bacterial sepsis. Pediatrics. 2012;129(5):1006‑1015.
[11] Camacho‑Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. 2013;60(2):367‑389.
[12] Wynn JL, Wong HR, Shanley TP, et al. Time for a neonatal‑specific consensus definition for sepsis. Pediatr Crit Care Med. 2014;15(6):523‑528.
[13] Saiman L, Ludington E, Pfaller MA, et al. Risk factors for Candida bloodstream infections among neonatal intensive care unit patients: implications for antifungal prophylaxis. Pediatr Infect Dis J. 2000;19(4):319‑324.
[14] Puopolo KM, Madoff LC, Eichenwald EC. Early‑onset sepsis principal outcomes: guidelines and clinical practice. J Perinatol. 2018;38(1):45‑51.
[15] Polin RA. Evaluation and management of neonates with suspected sepsis. Clin Perinatol. 2012;39(4):745‑762.
[16] Dong Y, Speer CP. Late‑onset neonatal sepsis: recent developments. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F257‑F263.
[17] Wang H, Liu X, Zhou S, et al. Antimicrobial resistance among neonatal sepsis pathogens in low‑ and middle‑income countries: a systematic review. J Glob Antimicrob Resist. 2021;25:108‑118.
[18] Cutland CL, McAuley R, et al. Group B Streptococcus disease in infants: clinical management and antibiotic strategies. Lancet Infect Dis. 2017;17(10):e279‑e291.
[19] Camacho‑Gonzalez A, Stoll BJ, et al. Gram‑negative neonatal sepsis: antibiotic strategies. Clin Perinatol. 2015;42(1):57‑73.
[20] Polin RA, Denson S, Brady MT; Committee on Fetus and Newborn. Red Book: 2021‑2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
[21] Hamdan HZ, Tamim H, Abdelhadi M, et al. Empiric antibiotics for neonatal sepsis in developing countries. Pediatr Infect Dis J. 2009;28(5):430‑435.
[22] Cantey JB, Wozniak PS. Antimicrobial stewardship in the neonatal intensive care unit. Clin Perinatol. 2018;45(1):91‑103.
[23] Russell AB, Sharland M, Heath PT. Antibiotic use in neonatal units: balancing risks and benefits. J Antimicrob Chemother. 2012;67(4):886‑893.
[24] Cotten CM. Adverse consequences of antibiotic use in newborns: understanding risk. Curr Opin Pediatrics. 2016;28(2):145‑152.
[25] Lutsar I, Chazallon C, Carducci FI, et al. Meropenem vs standard of care for neonatal sepsis: the NeoMero1 trial. Clin Infect Dis. 2020;70(7):1306‑1317.
[26] Hornik CP, Brozanski B, et al. Safety and effectiveness of cefotaxime versus gentamicin for neonatal sepsis. Pediatr Infect Dis J. 2016;35(8):837‑843.
[27] Skerk V, Puizina M, Brzica H, et al. Neonatal sepsis with multiresistant Gram‑negative pathogens: antibiotic challenges. J Chemother. 2021;33(1):20‑29.
[28] Med1.uz. Neonatal sepsis basics and treatment in newborns. Available from: https://med1.uz/articles/pediatrics/yangi-tugilgan-chaqaloqlarda-sepsis‑shoshilinch-davolash‑antibacterial‑therapy